PriceTargets.com logo

Quoin Pharmaceuticals - QNRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $17.33
  • Forecasted Upside: 281.79%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.54 As of 10/30/2026 04:58 PM ET
▲ +0.39 (9.40%)

This chart shows the closing price for QNRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quoin Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QNRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QNRX

Analyst Price Target is $17.33
▲ +281.79% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Quoin Pharmaceuticals in the last 3 months. The average price target is $17.33, with a high forecast of $20.00 and a low forecast of $14.00. The average price target represents a 281.79% upside from the last price of $4.54.

This chart shows the closing price for QNRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Quoin Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/4/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/2/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/1/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/19/2026Canaccord Genuity GroupInitiated CoverageBuy$18.00
10/16/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/12/2026BTIG ResearchInitiated CoverageBuy$14.00
10/12/2026BTIG ResearchInitiated CoverageBuy$14.00
9/23/2026Lake Street CapitalInitiated CoverageBuy$20.00
7/20/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
6/15/2026ThinkEquityInitiated CoverageBuy
4/22/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/11/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/14/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
3/15/2024Maxim GroupLower TargetBuy ➝ Buy$525.00 ➝ $140.00
3/10/2023LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
9/7/2022Alliance Global PartnersInitiated CoverageBuy$8,400.00
8/19/2022Citizens JmpLower Target$42,000.00 ➝ $6,300.00
8/19/2022Maxim GroupLower Target$10,500.00 ➝ $4,200.00
5/26/2022Maxim GroupLower Target$10,500.00
5/6/2022LADENBURG THALM/SH SHInitiated CoverageBuy$10,500.00
1/7/2022Maxim GroupInitiated CoverageBuy$26,250.00
12/15/2021Citizens JmpInitiated CoverageMarket Outperform$42,000.00
(Data available from 10/31/2021 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2026
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2026

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Quoin Pharmaceuticals logo
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
Read More

Today's Range

Now: $4.54
Low: $3.87
High: $4.54

50 Day Range

MA: $5.43
Low: $3.90
High: $7.87

52 Week Range

Now: $4.54
Low: $3.25
High: $23.50

Volume

36,567 shs

Average Volume

31,690 shs

Market Capitalization

$21.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Quoin Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Quoin Pharmaceuticals in the last year: BTIG Research, Canaccord Genuity Group Inc., Lake Street Capital, ThinkEquity, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for QNRX.

What is the current price target for Quoin Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Quoin Pharmaceuticals in the last year. Their average twelve-month price target is $17.33, suggesting a possible upside of 281.8%. Lake Street Capital has the highest price target set, predicting QNRX will reach $20.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $14.00 for Quoin Pharmaceuticals in the next year.
View the latest price targets for QNRX.

What is the current consensus analyst rating for Quoin Pharmaceuticals?

Quoin Pharmaceuticals currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for QNRX.

What other companies compete with Quoin Pharmaceuticals?

Other companies that are similar to Quoin Pharmaceuticals include Nutriband, Cingulate, Neumora Therapeutics, Cumberland Pharmaceuticals and MediciNova. Learn More about companies similar to Quoin Pharmaceuticals.

How do I contact Quoin Pharmaceuticals' investor relations team?

Quoin Pharmaceuticals' physical mailing address is 42127 Pleasant Forest Court, Ashburn, VA, 20148-7349. The company's listed phone number is +97299741444 and its investor relations email address is [email protected]. The official website for Quoin Pharmaceuticals is quoinpharma.com. Learn More about contacing Quoin Pharmaceuticals investor relations.